Asarfi Hospital Limited (**AHL**) is a leading regional healthcare provider in Eastern India, primarily serving the Dhanbad region of Jharkhand. Established in **2005**, the company operates a hub-and-spoke model centered on multi-specialty and oncology care, catering to a catchment area of approximately **30 lakh** people. The company listed on the **BSE SME platform** in **2023**, raising **₹26.94 Cr** to fund its transition from a regional hospital to a high-tech tertiary care hub. --- ### **Core Infrastructure & Specialized Care Units** AHL currently operates **330 beds** across two specialized units in Dhanbad, Jharkhand. The company is distinguished by its "first-mover" advantage in bringing advanced medical technology to the state. | Feature | Super-Specialty Unit (Baramuri) | Cancer Institute (Ranguni) | |:---|:---|:---| | **Established** | 2008 | 2024 | | **Current Capacity** | **265 Beds** | **65 Beds** | | **Occupancy (Q3'FY26)** | **61%** | **37%** | | **ARPOB (Q3'FY26)** | **₹24,293** | **₹43,240** | | **ALOS (Average Stay)** | **4.3 Days** | **4.6 Days** | | **Key Focus** | Cardiology, Neuro, Ortho, OBGYN | Medical, Surgical, & Radiation Oncology | **Technological Leadership:** * **Radiation Oncology:** Operates Jharkhand’s first **Varian True Beam** Linear Accelerator for precision therapy (IMRT, VMAT, SRS, SBRT). * **Diagnostics:** Equipped with a **Siemens 64-slice PET CT** and **HDR Brachytherapy** units. * **Future Upgrades:** Installation of a **GE Dual-Detector SPECT Gamma Camera** (by March 2026) and a **Philips Azurion 5 M12 Cath Lab** with **IVUS** capability. --- ### **Revenue Streams & Service Mix** AHL derives revenue from a diversified mix of inpatient (IPD), outpatient (OPD), and ancillary services. * **Clinical Specialties:** Cardiology, Gastroenterology, Neurosciences, Nephrology, and Pulmonology. * **Maternal & Child Health:** Comprehensive Obstetrics, Gynaecology, and Neonatology (NICU) services. * **Pharmacy Operations:** A significant vertical contributing approximately **25%** of total revenue. * **Strategic Outsourcing:** AHL improves efficiency by partnering with specialists for non-core units, such as the **April 2025** agreement with **Sharp Sight Eye Hospitals** to manage Ophthalmology. * **Public-Private Integration:** The hospital is heavily empaneled with **Ayushman Bharat**, **MGBUY**, **Coal India**, and **Indian Railways**, ensuring a steady flow of high-volume patient traffic. --- ### **Vision 2027: The Quaternary Care Roadmap** The company is executing a multi-dimensional growth strategy to evolve into a leading hub for advanced quaternary care in Eastern India. **1. Capacity & Clinical Expansion:** * **Cancer Institute Scaling:** Expanding from **65 to 150 beds** by **FY26**. This is an asset-light expansion with a projected capex of only **₹2-3 crores**, as the core building infrastructure is already complete. * **Organ Transplants:** Signed an MoU with **Gleneagles Hospital, Chennai** to establish Jharkhand’s first **Multi-Organ Transplant Unit** (Heart, Lung, Liver, Kidney). * **New Verticals:** Launching a **Bone Marrow Transplant (BMT)** unit and an **IVF vertical** to capture high-margin specialized segments. **2. Educational & Academic Integration:** * **Medical Education:** Granted **NBEMS** accreditation in **November 2025** for **DNB** and Diploma courses in Surgery, Radiology, OBGYN, and Pediatrics. * **Ranchi Smart City Project:** Acquired **5.6 acres** for a **Healthcare Management & Research Institute**, with courses slated for **FY28**. * **Ancillary Revenue:** Developing a **600+ capacity student hostel** (42,000 sq. ft.) expected to generate **₹3.5 crore** in annual rental revenue by **FY27**. **3. Geographic Diversification:** * Exploring **Operations & Management (O&M) contracts** and acquisitions to expand the brand into **Bihar** and **Eastern Uttar Pradesh**. --- ### **Financial Performance & Scalability** AHL has demonstrated significant margin expansion and revenue growth following its IPO. The company maintains a healthy **Debt-to-Equity ratio of 0.60** (FY25). **Consolidated Financial Summary:** | Metric | FY24 (Actual) | FY25 (Actual) | H1'FY26 (Actual) | |:---|:---|:---|:---| | **Revenue from Operations** | ₹84.40 Cr | **₹120.57 Cr** | **₹80.60 Cr** | | **EBITDA Margin** | 19% | **20%** | **20%** | | **Profit After Tax (PAT)** | ₹4.16 Cr | **₹10.58 Cr** | **₹7.32 Cr** | | **PAT Margin** | 5% | **9%** | **9%** | | **ROCE** | - | **14%** | - | **Growth Targets (FY27):** * **Revenue Target:** **₹200+ Crore** * **EBITDA Margin Target:** **25% – 27%** * **PAT Margin Target:** **13% – 15%** * **Total Bed Capacity:** **500 Beds** --- ### **Operational Metrics & Working Capital** * **Patient Volumes:** IPD volumes more than doubled in **H1'FY26** to **12,361** patients. * **ARPOB Dynamics:** While the Super-Specialty unit maintains an ARPOB of **₹24,293**, the Cancer Hospital’s ARPOB surged to **₹43,240** in **Q3'FY26**, reflecting the shift toward high-complexity oncology cases. * **Receivables Management:** Average collection period stands at **105 days**, primarily due to government empanelments (**ESI, Railways, and BCCL**). * **Financing:** Recently secured a **₹4.68 Cr** SBI term loan for Cath Lab upgrades and maintains a **₹28.50 Cr** HDFC loan for cancer equipment under the **LGSCAS Scheme**. --- ### **Risk Assessment & Mitigation** **1. Land Litigation (Ranguni Site):** The **9.55-acre** land leased from **JIADA** for the Cancer Hospital was subject to a title dispute. However, in **March 2025**, the **High Court of Jharkhand** deleted AHL from the array of parties in the primary litigation, ruling that current decisions are **not binding** on the company. While plaintiffs have threatened a "fresh suit," the immediate legal threat to project viability has significantly receded. **2. Regulatory Compliance:** Auditors issued a **Qualified Opinion** in **May 2024** regarding the lack of an **automated audit trail** in the accounting software. Management is tasked with upgrading internal financial controls to meet **Rule 3(1) of the Companies (Accounts) Rules**. **3. Foreign Exchange Exposure:** The company carries a liability of **₹16.57 crore** to **Varian Medical Systems** for imported machinery. This risk is mitigated through **forward contracts** with **HDFC Bank** to hedge against currency volatility. **4. Concentration Risk:** Currently, operations are concentrated in the Dhanbad region. The strategy to move into **Ranchi** and explore **O&M contracts** in neighboring states is the primary mitigation for regional geographic risk.